Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | WIZ | O95785 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675665 | 1.00 | CRBN (0.51) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL29823049 | 1.00 | CRBN (0.51) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL27302546 | 1.00 | CRBN (0.51) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL31027771 | 0.98 | IKZF2 (0.52) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL27424058 | 0.98 | IKZF2 (0.52) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL20231030 | 0.95 | CRBN (0.49) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL20235034 | 0.95 | CRBN (0.49) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL30942467 | 0.94 | IKZF2 (0.49) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL27302541 | 0.94 | IKZF2 (0.49) | CRBNIKZF2DDB1CSNK1A1WIZ | |
| SCHEMBL29648391 | 0.94 | IKZF2 (0.52) | CRBNIKZF2DDB1CSNK1A1WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 276/4885IKZF2 2302/4885DDB1 357/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | CRBN 276/4885IKZF2 2302/4885DDB1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.